The literature demonstrates the therapeutic and prognostic value of biomarkers involved in the bio-molecular mechanism of urothelial carcinoma and other urinary tract tumors like CXR2 and CXR3 in renal cell carcinoma and prostate-specific antigen (PSA) in prostatic adenocarcinoma (6-11). This evidence concerns the gene KLK3 and prostate adenocarcinoma.